Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Spago Nanomedical starts phase IIa study in endometriosis

Spago Nanomedical

Lund-based Spago Nanomedical has recently been given the go-ahead to initiate a phase IIa study with the product candidate SN132D for the diagnosis of the widespread disease endometriosis. Patient recruitment has already begun and the company expects to be able to include the first patient shortly. BioStock talked to CEO Mats Hansen about the new area and the upcoming study, but also about the SPAGOPIX-01 study in breast cancer that recently was concluded.

Read the full interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2022/12/spago-nanomedical-starts-phase-iia-study-in-endometriosis/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.